EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Antisense phosphorothioate oligodeoxynucleotides: Introductory concepts and possible molecular mechanisms of toxicity






Toxicology Letters (Shannon) 82-83(SPEC ISSUE): 419-424

Antisense phosphorothioate oligodeoxynucleotides: Introductory concepts and possible molecular mechanisms of toxicity

Over the past 5 years or so, much attention has been given to the possible use of synthetic antisense oligonucleotide analogs as a new class of therapeutic agents that function by sequence-specific inhibition of genetic expression. The basic design concepts which underline this novel approach to drug discovery are briefly described herein, together with some of the chemical, biochemical, and pharmacological aspects of phosphorothioate oligodeoxynucleotides that are first-generation antisense compounds now under clinical investigation. Possible molecular mechanisms of toxicity for this class, and other structural types of antisense compounds are discussed with the hope of stimulating interest in future toxicological studies in this emerging area of drug development.

Accession: 009770898

PMID: 8597087

DOI: 10.1016/0378-4274(95)03571-0

Download PDF Full Text: Antisense phosphorothioate oligodeoxynucleotides: Introductory concepts and possible molecular mechanisms of toxicity



Related references

Zon, G., 1995: Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity. Over the past 5 years or so, much attention has been given to the possible use of synthetic antisense oligonucleotide analogs as a new class of therapeutic agents that function by sequence-specific inhibition of genetic expression. The basic desig...

Hebb, M.O.; Robertson, H.A., 1997: End-capped antisense oligodeoxynucleotides effectively inhibit gene expression in vivo and offer a low-toxicity alternative to fully modified phosphorothioate oligodeoxynucleotides. Sulfur modification of oligodeoxynucleotides produces nuclease resistance but also leads to toxic effects when these compounds are administered in vivo. To assess their potential as viable alternatives to full phosphorothioate derivatives, we have...

Woolf, T.M.; Jennings, C.G.; Rebagliati, M.; Melton, D.A., 1990: The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos. The properties of antisense phosphorothioate and unmodified oligodeoxynucleotides have been studied in Xenopus oocytes and embryos. We find that phosphorothioates, like unmodified oligodeoxynucleotides, can degrade Vg1 mRNA in oocytes via an endog...

Li, Q.; Chen, R.; Sun, Y.; Hu, Y., 2007: Separation of phosphodiester oligodeoxynucleotides and phosphorothioate antisense oligodeoxynucleotides by capillary zone electrophoresis at low pH. Oligodeoxynucleotides (ODNs) may possess biological activity in vivo, and are used for the cancer therapeusis. Synthesized ODNs contains many by-products, and so their purity check and resolution of single-base, i. e., the separation of ODNs diffe...

Hertl, M.; Neckers, L.M.; Katz, S.I., 1995: Inhibition of interferon-gamma-induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects. Expression of intercellular adhesion molecule-1 (ICAM-1) by keratinocytes is an important event in the pathogenesis of T-cell-mediated inflammatory skin diseases. To determine if ICAM-1 expression could be selectively modulated, two antisense phos...

Benimetskaya, L.; Miller, P.; Benimetsky, S.; Maciaszek, A.; Guga, P.; Beaucage, S.L.; Wilk, A.; Grajkowski, A.; Halperin, A.L.; Stein, C.A., 2001: Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha and antisense bcl-2 phosphorothioate oligodeoxynucleotides Relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Isis 3521 and G3139 are 20- and 18-mer phosphorothioate oligonucleotides, respectively, targeted to the protein kinase C (PKC)-alpha and bcl-2 mRNAs. Treatment of T24 bladder and PC3 prostate carcinoma cells with full-length and 3'-truncation...

Geary, R.S.; Yu, R.Z.; Levin, A.A., 2001: Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Phosphorothioate (PS) oligodeoxynucleotides represent the class of antisense drugs most advanced in development and clinical testing. Exploitation of antisense oligonucleotide technology for development of rationally designed therapeutic drugs has...

Stein, C.A., 1996: Exploiting the potential of antisense: beyond phosphorothioate oligodeoxynucleotides. Phosphorothioate oligodeoxynucleotides, designed as nuclease-resistant antisense agents, appear to have a number of surprising biological effects that are unrelated to their intended antisense activity. These effects may be useful in themselves, b...

Krieg, A.M.; Stein, C.A., 1995: Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?. Antisense Research and Development 5(4): 241-241

Stein, C.A., 1996: Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. This study compared the Functional Independence Measure (FIM) scores of traumatic (n=12) and vascular (n=12) unilateral lower limb amputees at admission and discharge from a rehabilitation facility. FIM scores that were measured were amputation FI...